Home › Funds › DME Capital Management, LP › GANX

DME Capital Management, LP position in GANX

GAIN THERAPEUTICS INC · Health Care

DME Capital Management, LP reported holding 566,130 shares of GANX (GAIN THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$1.1M, representing 0.03% of its reported portfolio and ranking #45 among its reported holdings. DME Capital Management, LP has disclosed GANX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

Latest position (Q2 2026)566.13K sh
Reported value held$1.15M
Portfolio Weight0.03%
First reportedQ1 2024
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How DME Capital Management, LP's GANX position evolved

DME Capital Management, LP first disclosed a stake in GANX in Q1 2024 at 566,130 shares (US$2.1M). Across 10 filings, DME Capital Management, LP held the position steady without any share-count change. The most recent filing (Q2 2026) shows 566,130 shares valued at US$1.1M.

Quarter by quarter

QuarterSharesValueChange
Q1 2024 566.13K $2.13M New
Q2 2024 566.13K $724.65K Hold
Q3 2024 566.13K $1.01M Hold
Q4 2024 566.13K $1.22M Hold
Q1 2025 566.13K $1.08M Hold
Q2 2025 566.13K $1.02M Hold
Q3 2025 566.13K $1.00M Hold
Q4 2025 566.13K $1.82M Hold
Q1 2026 566.13K $1.10M Hold
Q2 2026 566.13K $1.15M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About GANX and 13F data

GANX (GAIN THERAPEUTICS INC) is a Health Care company. 44 other funds we track also report a position in GANX — the largest reported positions include Potomac Capital Management, Inc. (US$1.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding GANX

All GANX fund holders →

FAQ

How long has DME Capital Management, LP held GANX?

DME Capital Management, LP has disclosed GANX holdings in 10 of the last 10 reported quarters, going back to Q1 2024.

What is DME Capital Management, LP's current position in GANX?

As of Q2 2026, DME Capital Management, LP holds 566.13K shares of GANX (GAIN THERAPEUTICS INC), valued at $1.15M, representing 0.03% of its reported portfolio and ranking #45.

Has DME Capital Management, LP been buying or selling GANX?

In the latest 13F filing (Q2 2026), DME Capital Management, LP held unchanged its position in GANX.

Which other funds hold GANX?

Other major institutional holders of GANX include Potomac Capital Management, Inc., among 44 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.